WVE Valuation

WAVE Life Sciences Ltd

Add to Watchlist

Advanced Chart

8.400

+0.01(0.119%)1D

Overview
Forecast
Valuation
Earnings

WVE Relative Valuation

WVE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, WVE is overvalued; if below, it's undervalued.

Historical Valuation

WAVE Life Sciences Ltd (WVE) is now in the Undervalued zone, suggesting that its current forward PS ratio of 22.35 is considered Undervalued compared with the five-year average of -4.86. The fair price of WAVE Life Sciences Ltd (WVE) is between 2678.47 to 2683.35 according to relative valuation methord. Compared to the current price of 8.40 USD , WAVE Life Sciences Ltd is Undervalued By 99.69%.

Relative Value

Fair Zone

2678.47-2683.35

Current Price：8.40

99.69%

Undervalued

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

7.53

P/B

Median3y

-36.01

Median5y

-130.80

-14.02

FCF Yield

Median3y

-14.27

Median5y

-26.97

Competitors Valuation Multiple

The average P/S ratio for WVE's competitors is 30409.86, providing a benchmark for relative valuation. WAVE Life Sciences Ltd Corp (WVE) exhibits a P/S ratio of 21.90, which is -99.93% above the industry average. Given its robust revenue growth of -26.82%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

WVE.O

WAVE Life Sciences Ltd

21.90

Average P/S: 30409.86

-26.82%